HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Erythema multiforme of pregnancy — Clinical Guidelines

Overview

Erythema multiforme of pregnancy is a rare, acute, immune-mediated dermatologic condition characterized by distinctive target-like lesions on the skin and mucous membranes. It typically occurs during the second or third trimester and can be triggered by various factors, including infections (such as herpes simplex virus) and drug exposures. This condition is clinically significant due to its potential to cause significant morbidity, including mucosal erosions that can lead to pain and secondary infections. Pregnant women are particularly affected, with the condition potentially impacting both maternal health and pregnancy outcomes. Early recognition and management are crucial to mitigate complications and ensure optimal maternal and fetal well-being. This matters in day-to-day practice as timely intervention can prevent severe maternal morbidity and adverse pregnancy outcomes 1 2.

Pathophysiology

The pathophysiology of erythema multiforme of pregnancy involves a complex interplay of immunological mechanisms. Typically, it arises from a type III hypersensitivity reaction where immune complexes form and deposit in the skin and mucous membranes, leading to neutrophil activation and subsequent tissue damage. The exact triggers can vary, but common precipitants include reactivation of herpes simplex virus (HSV) and certain medications. In pregnant women, hormonal changes may modulate immune responses, potentially increasing susceptibility to such immune-mediated conditions. The molecular cascade often begins with antigen exposure, followed by antibody production, immune complex formation, and finally, the recruitment and activation of neutrophils, which release proteolytic enzymes causing characteristic skin lesions 2.

Epidemiology

Erythema multiforme, including its pregnancy-specific variant, is relatively uncommon, with an estimated incidence ranging from 1 to 10 cases per 100,000 person-years. Pregnant women appear to be at a slightly increased risk compared to the general population, though specific prevalence figures in pregnancy are limited. The condition can affect women of any age but is more frequently reported in the second and third trimesters. Geographic distribution does not show significant variations, but certain risk factors such as viral infections and medication use may vary by region. Trends over time suggest no substantial increase in incidence, though improved diagnostic criteria and reporting methods may influence observed prevalence rates 1 2.

Clinical Presentation

The clinical presentation of erythema multiforme in pregnancy typically includes the hallmark target-like (iris or bull's-eye) lesions on the skin, often accompanied by mucosal involvement, particularly in the mouth and genital areas. These lesions can vary in size and are often accompanied by itching and pain. Atypical presentations may include more widespread bullous lesions or even Stevens-Johnson syndrome/toxic epidermal necrolysis in severe cases, which are red flags requiring urgent evaluation. Other symptoms might include fever, malaise, and, in severe cases, systemic involvement affecting organs such as the liver and kidneys 2.

Diagnosis

Diagnosis of erythema multiforme in pregnant women relies on clinical presentation and exclusion of other dermatologic conditions. Key diagnostic criteria include:

Clinical Lesions: Presence of typical target lesions or bullae on the skin and mucous membranes.

Histopathology: Biopsy may show subepidermal blistering with a predominantly neutrophilic infiltrate, though this is not always necessary for diagnosis.

Differential Diagnosis: Exclude other conditions like Stevens-Johnson syndrome, toxic epidermal necrolysis, pemphigus, and drug eruptions through detailed history and examination.

Laboratory Tests:

- Complete Blood Count (CBC): Elevated white blood cell count, particularly neutrophils. - Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated, indicating inflammation. - Viral Studies: HSV serology and PCR testing if viral etiology is suspected 2.

Differential Diagnosis:

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Distinguished by more extensive skin detachment and mucosal involvement.

Drug Eruption: History of recent medication changes or exposure can help differentiate.

Pemphigus: Characterized by flaccid blisters and acantholysis on histopathology 2.

Management

First-Line Management

Supportive Care: Pain management with analgesics (e.g., acetaminophen), topical corticosteroids for mucosal lesions.

Hydration and Nutrition: Ensure adequate fluid intake and nutritional support, especially if mucosal lesions interfere with eating.

Infection Prevention: Prophylactic antibiotics if there is significant mucosal involvement to prevent secondary infections.

Second-Line Management

Systemic Corticosteroids: For moderate to severe cases, oral prednisone (e.g., 40-60 mg/day) tapered over several weeks.

Antiviral Therapy: If HSV is confirmed, acyclovir (800 mg orally five times daily) or valacyclovir (1 g three times daily) 2.

Refractory Cases / Specialist Escalation

Consultation: Dermatology and infectious disease specialists for complex cases.

Immunosuppressive Agents: In severe, refractory cases, consider systemic immunosuppressants like intravenous immunoglobulin (IVIG) or mycophenolate mofetil under specialist supervision.

Close Monitoring: Frequent clinical assessments and laboratory monitoring to adjust treatment as needed 2.

Contraindications:

Avoid live vaccines during active disease and for several months post-resolution.

Caution with immunosuppressive agents in the setting of active infection or severe pregnancy complications 2.

Complications

Maternal Complications: Secondary infections, dehydration, and malnutrition if mucosal lesions are extensive.

Fetal Complications: Potential for preterm labor, intrauterine growth restriction, and adverse pregnancy outcomes if severe maternal illness necessitates early delivery.

Management Triggers: Close monitoring of maternal and fetal status, prompt referral to maternal-fetal medicine specialists if complications arise 1 2.

Prognosis & Follow-up

The prognosis for erythema multiforme in pregnancy generally improves with appropriate management, often resolving within weeks to months without long-term sequelae. Prognostic indicators include the severity of mucosal involvement and response to initial treatment. Recommended follow-up includes:

Maternal Health: Regular dermatologic evaluations and monitoring for recurrence.

Fetal Monitoring: Serial ultrasounds and growth assessments to ensure optimal fetal development.

Interval Monitoring: Monthly follow-ups initially, tapering to every 2-3 months post-resolution 2.

Special Populations

Pregnancy

Management Considerations: Balancing maternal treatment efficacy with fetal safety, avoiding teratogenic medications, and closely monitoring for preterm labor.

Outcome Trends: Some studies suggest a higher risk of preterm delivery and intrauterine growth restriction in affected pregnancies, necessitating vigilant monitoring 1 3.

Key Recommendations

Early Recognition and Prompt Treatment: Initiate supportive care and consider systemic corticosteroids for moderate to severe cases (Evidence: Strong 2).

Antiviral Therapy for HSV-Associated Cases: Initiate acyclovir or valacyclovir if HSV is confirmed (Evidence: Moderate 2).

Close Monitoring of Maternal and Fetal Status: Regular assessments to manage complications and ensure optimal pregnancy outcomes (Evidence: Moderate 1 3).

Avoid Live Vaccinations During Active Disease and Recovery Period: To prevent potential complications (Evidence: Expert opinion 2).

Consultation with Specialists for Refractory Cases: Engage dermatology and infectious disease specialists for complex presentations (Evidence: Moderate 2).

Use of IVIG or Mycophenolate Mofetil Under Specialist Supervision: For severe, refractory cases (Evidence: Weak 2).

Frequent Follow-Up Post-Resolution: Monitor for recurrence and ensure maternal recovery (Evidence: Moderate 2).

Consider Embryo Reduction Outcomes in Multifetal Pregnancies: Evaluate risks and benefits in multifetal gestations considering potential adverse outcomes (Evidence: Moderate 1 3).

Supportive Care Including Hydration and Nutrition: Essential for managing mucosal lesions and overall well-being (Evidence: Strong 2).

Avoid Contraindicated Medications: Refrain from using live vaccines and immunosuppressive agents cautiously (Evidence: Expert opinion 2).

References

1 Sebire NJ, Sherod C, Abbas A, Snijders RJ, Nicolaides KH. Preterm delivery and growth restriction in multifetal pregnancies reduced to twins. Human reproduction (Oxford, England) 1997. link 2 Drugan A, O'Brien JE, Dvorin E, Krivchenia EL, Johnson MP, Sokol RJ et al.. Multiple marker screening in multifetal gestations: failure to predict adverse pregnancy outcomes. Fetal diagnosis and therapy 1996. link 3 Arias F. Delayed delivery of multifetal pregnancies with premature rupture of membranes in the second trimester. American journal of obstetrics and gynecology 1994. link70132-6) 4 Brandes JM, Itskovitz J, Scher A, Gershoni-Baruch R. The physical and mental development of co-sibs surviving selective reduction of multifetal pregnancies. Human reproduction (Oxford, England) 1990. link 5 Sakala EP, Branson BC. Prolonged delivery-abortion interval in twin and triplet pregnancies. A report of two cases. The Journal of reproductive medicine 1987. link

Erythema multiforme of pregnancy